| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2006.10.5122 |
| P698 | PubMed publication ID | 17878479 |
| P50 | author | Chandra Belani | Q40073451 |
| Miloš Pešek | Q42632027 | ||
| John V Heymach | Q88721314 | ||
| Roy S. Herbst | Q89006575 | ||
| P2093 | author name string | Bruce E Johnson | |
| Shirish Gadgeel | |||
| Diane Prager | |||
| Jeannie Hou | |||
| Sarah J Kennedy | |||
| István Bodrogi | |||
| Edit Csada | |||
| Jaromír Roubec | |||
| Irena Spásová | |||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| lung cancer | Q47912 | ||
| docetaxel | Q420436 | ||
| vandetanib | Q7914515 | ||
| P304 | page(s) | 4270-4277 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer | |
| P478 | volume | 25 |
| Q43504942 | A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer |
| Q54604259 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. |
| Q48374393 | A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. |
| Q41652822 | A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study |
| Q42359608 | Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis |
| Q39102975 | Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines |
| Q39013156 | Alternative designs for clinical trials in rare diseases |
| Q24657761 | Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment |
| Q38077494 | An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents |
| Q37435385 | Angiogenesis in the treatment of non-small cell lung cancer |
| Q35076198 | Angiogenesis inhibitors in the treatment of non-small cell lung cancer |
| Q34821321 | Anti-angiogenic agents in the treatment of non-small cell lung cancer |
| Q38153445 | Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective |
| Q34854658 | Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. |
| Q36316939 | Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway |
| Q36909227 | Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma |
| Q37624732 | Antivascular agents for non-small-cell lung cancer: current status and future directions. |
| Q54979771 | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma. |
| Q28085104 | Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? |
| Q45246341 | Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study |
| Q40939787 | Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. |
| Q38062018 | Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies |
| Q37900923 | Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q34316070 | Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials |
| Q38077126 | Clinical meta-analyses of targeted therapies in adenocarcinoma |
| Q37509502 | Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial |
| Q39499854 | Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. |
| Q37204970 | Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications |
| Q39850353 | Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance |
| Q41892153 | Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. |
| Q37701719 | Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials |
| Q37790985 | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| Q36464597 | Cutaneous pigmentation after photosensitivity induced by vandetanib therapy |
| Q37418739 | DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study |
| Q34578277 | Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. |
| Q37242661 | Docetaxel in the treatment of advanced non-small-cell lung cancer. |
| Q39139831 | Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis |
| Q33923405 | Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer |
| Q37240726 | EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer |
| Q33418555 | Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. |
| Q34826532 | Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis |
| Q26801118 | Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review |
| Q33429478 | Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer |
| Q36482542 | Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer |
| Q37431620 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer |
| Q36402837 | Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer |
| Q28972291 | Evolving Therapies and FAK Inhibitors for the Treatment of Cancer |
| Q37986608 | Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials |
| Q36822204 | HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer |
| Q37263338 | Hypoxia, angiogenesis, and lung cancer |
| Q50718626 | Identification of new candidate drugs for lung cancer using chemical-chemical interactions, chemical-protein interactions and a K-means clustering algorithm. |
| Q28079328 | Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients |
| Q36729895 | Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials |
| Q49244147 | Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. |
| Q38756931 | Incorporating VEGF-targeted therapy in advanced urothelial cancer |
| Q55425422 | Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. |
| Q37081427 | Integrating biologically targeted therapy in head and neck squamous cell carcinomas |
| Q37512570 | Investigational agents in the management of non-small cell lung cancer. |
| Q33395482 | Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer |
| Q41263498 | Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib |
| Q37483987 | Mode of action and clinical impact of VEGF signaling inhibitors |
| Q37347532 | Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy |
| Q35346839 | Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses |
| Q35660763 | New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond |
| Q37357304 | New avenues for second-line treatment of metastatic non-small-cell lung cancer |
| Q35667806 | New molecular targeted therapies for advanced non-small-cell lung cancer. |
| Q38014533 | New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment |
| Q37624735 | Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development? |
| Q42977199 | One more fallen star--ZODIAC and its implications |
| Q46252282 | Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer |
| Q37799826 | Personalized medicine for non-small-cell lung cancer. |
| Q37957744 | Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. |
| Q37170005 | Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma |
| Q42944301 | Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment |
| Q34488803 | Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma |
| Q36677934 | Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers |
| Q36936139 | Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma |
| Q39816573 | Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan |
| Q37471538 | QT interval prolongation among patients treated with angiogenesis inhibitors |
| Q35677270 | QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. |
| Q38223668 | QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. |
| Q33903078 | Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. |
| Q37789579 | Recent Development of Molecular-Targeted Drugs in Lung Cancer |
| Q21092930 | Recent advances of novel targeted therapy in non-small cell lung cancer |
| Q37118936 | Recurrent head and neck cancer: current treatment and future prospects. |
| Q51088833 | Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure. |
| Q38678038 | Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials |
| Q47128966 | Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials |
| Q35187896 | Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis |
| Q34352627 | Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials |
| Q37042424 | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review |
| Q36965055 | Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours |
| Q92559327 | Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis |
| Q55069554 | Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. |
| Q26775876 | Second-line combination therapies in nonsmall cell lung cancer without known driver mutations |
| Q37579650 | Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs |
| Q37760357 | Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? |
| Q35628597 | Targeted therapies for non-small cell lung cancer: an evolving landscape |
| Q36990546 | Targeted therapies in non-small cell lung cancer |
| Q42845473 | Targeted therapies: Molecular selection for 'smart' study design in lung cancer |
| Q38964908 | Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer. |
| Q35584074 | Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer |
| Q37435616 | Targeting aromatase and estrogen signaling in human non-small cell lung cancer |
| Q37863629 | Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors |
| Q39799414 | Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines |
| Q36526512 | The VEGF pathway in cancer and disease: responses, resistance, and the path forward. |
| Q45230734 | The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials |
| Q35649624 | The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis |
| Q43794742 | The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials |
| Q37818251 | Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. |
| Q35667802 | Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? |
| Q37851992 | Update on new drugs in small cell lung cancer |
| Q33875268 | Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology |
| Q37374479 | Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer |
| Q64237947 | VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review |
| Q37177871 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma |
| Q37734665 | Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway |
| Q38236623 | Vandetanib as a potential treatment for breast cancer. |
| Q38016190 | Vandetanib for the treatment of lung cancer |
| Q37912188 | Vandetanib for the treatment of non-small-cell lung cancer |
| Q41167117 | Vandetanib in advanced non small cell lung cancer: a promise unfulfilled |
| Q35576189 | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial |
| Q43962535 | Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature |
| Q45855897 | Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study |
| Q34147360 | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. |
| Q54573214 | Vandetanib: first global approval. |
| Q37788428 | Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer |
| Q55464446 | [Vandetanib for advanced non-small cell lung cancer: a meta-analysis]. |
Search more.